This study showed that the realization of biomarker testing including tumor genotyping and PD-L1 status research during the diagnosis of advanced or metastatic non-squamous NSCLC has become widespread over time and is now a routine practice. The gene discussed is CD274; the disease is non-small cell lung carcinoma.